Wave Life Sciences Ltd. (NASDAQ:WVE) Shares Purchased by BNP Paribas Financial Markets

BNP Paribas Financial Markets raised its position in Wave Life Sciences Ltd. (NASDAQ:WVE) by 477.7% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 41,828 shares of the company’s stock after purchasing an additional 34,588 shares during the quarter. BNP Paribas Financial Markets’ holdings in Wave Life Sciences were worth $343,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors also recently made changes to their positions in WVE. Charles Schwab Investment Management Inc. boosted its holdings in Wave Life Sciences by 209.1% during the third quarter. Charles Schwab Investment Management Inc. now owns 844,617 shares of the company’s stock worth $6,926,000 after buying an additional 571,345 shares in the last quarter. Privium Fund Management B.V. bought a new position in shares of Wave Life Sciences during the 3rd quarter valued at $400,000. FMR LLC raised its holdings in shares of Wave Life Sciences by 174.5% during the 3rd quarter. FMR LLC now owns 1,540,190 shares of the company’s stock valued at $12,630,000 after purchasing an additional 979,110 shares in the last quarter. Moody Aldrich Partners LLC raised its holdings in Wave Life Sciences by 69.0% in the 3rd quarter. Moody Aldrich Partners LLC now owns 303,062 shares of the company’s stock worth $2,485,000 after acquiring an additional 123,703 shares during the period. Finally, SG Americas Securities LLC bought a new position in Wave Life Sciences in the 2nd quarter worth $668,000. Institutional investors and hedge funds own 89.73% of the company’s stock.

Analyst Ratings Changes

Several analysts have recently weighed in on WVE shares. Wells Fargo & Company lifted their target price on shares of Wave Life Sciences from $11.00 to $22.00 and gave the company an “overweight” rating in a research report on Wednesday, October 16th. B. Riley boosted their price target on shares of Wave Life Sciences from $19.00 to $22.00 and gave the stock a “buy” rating in a research note on Monday, November 4th. Leerink Partners boosted their price objective on shares of Wave Life Sciences from $20.00 to $22.00 and gave the company an “outperform” rating in a report on Wednesday, October 16th. JPMorgan Chase & Co. upped their price target on shares of Wave Life Sciences from $13.00 to $17.00 and gave the company an “overweight” rating in a report on Thursday, October 17th. Finally, Royal Bank of Canada increased their target price on shares of Wave Life Sciences from $7.00 to $15.00 and gave the stock a “sector perform” rating in a report on Monday, October 21st. One analyst has rated the stock with a sell rating, one has issued a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $22.22.

Wave Life Sciences Stock Down 3.0 %

Shares of Wave Life Sciences stock opened at $13.44 on Friday. The company has a market capitalization of $2.05 billion, a price-to-earnings ratio of -12.11 and a beta of -1.21. Wave Life Sciences Ltd. has a 12-month low of $3.50 and a 12-month high of $16.74. The firm’s 50-day moving average price is $13.80 and its two-hundred day moving average price is $8.74.

Insiders Place Their Bets

In related news, CFO Kyle Moran sold 17,146 shares of the firm’s stock in a transaction that occurred on Wednesday, September 25th. The shares were sold at an average price of $9.00, for a total value of $154,314.00. Following the completion of the transaction, the chief financial officer now owns 19,777 shares in the company, valued at $177,993. This trade represents a 46.44 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Paul Bolno sold 50,000 shares of the firm’s stock in a transaction that occurred on Monday, November 25th. The shares were sold at an average price of $15.00, for a total transaction of $750,000.00. Following the completion of the transaction, the chief executive officer now owns 217,351 shares of the company’s stock, valued at approximately $3,260,265. This trade represents a 18.70 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 453,690 shares of company stock worth $6,425,883 over the last ninety days. Corporate insiders own 29.10% of the company’s stock.

About Wave Life Sciences

Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders.